LongeVC's Sergey Jakimov Featured in Labiotech Article on European Biotech VC Trends
Our managing partner, Sergey Jakimov, was quoted in a recent Labiotech article analyzing how European biotech VCs are adapting to market pressures through strategic consolidations and disciplined investing.
Sergey commented on the Asabys-Aliath integration as "a strategic move to strengthen Europe's ecosystem against U.S. dominance," in response to funding declines and the selective presence of limited partners. He noted such moves help firms deploy larger capital for extended R&D cycles in biotech's capital-intensive environment.
According to Sergey, the current European biopharma VC landscape is "cautiously resilient but selective, with funding stabilizing at lower levels" following the Q1 2025 downturn. He highlighted Europe's strengths in academic hubs and policies, such as Horizon Europe, while acknowledging challenges in IPOs and talent retention.